Physician profile
Ramey Hito
NPI 1053544122
$211.81
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $13.61 · 2022: $12.15.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $27.78 | 2019 | |
| Abbvie INC. | $26.53 | 2019-2022 | |
| Novo Nordisk INC | $23.84 | 2019 | |
| Genentech USA, INC. | $23.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.13 | 2019 | |
| Pfizer INC. | $15.51 | 2019 | |
| Glaxosmithkline, LLC. | $15.49 | 2019 | |
| Intersect Ent, INC. | $13.05 | 2019 | |
| Abbott Laboratories | $13.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramey Hito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.